Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Sep
28
Today In Oncology
SRS Is a Reasonable Option for Patients With SCLC and Brain Metastases
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma
FDA Advisory Committee Votes in Favor of Approval of Multi-Cancer Early Detection Test
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo